Pipeline

SLC-391

AXL Inhibitor

SLC-391 is a novel, highly selective small-molecule compound that inhibits the activity of AXL, a receptor tyrosine kinase of the TAM family, which is over-expressed or over-activated in almost all cancer types and directly correlates with tumor stage and prognosis. AXL appears to play a dual regulatory role, controlling the initiation and progression of tumor development and the associated antitumor responses of diverse immune cells. As such, AXL represents an intriguing protein to simultaneously target the tumor cells and the immune cells in the TME.

Program

Target and Modality

Indication

Discovery

Pre-clinical

Phase I/Ib

Phase II

Phase III

Collaborator

SLC-391

AXL small-molecule kinase inhibitor

NSCLC

Combination therapy with PD-1 Antibody in NSCLC

AML / MDS

Monotherapy
Combination therapy with PD-1 Antibody in NSCLC
Phase I/Ib
Monotherapy
Phase I/Ib

SLC-0111

Carbonic Anhydrase IX (CAIX) Inhibitor

SLC-0111 is a first-in-class small molecule inhibitor of Carbonic Anhydrase IX (CAIX), which is only expressed on the surface of human tumor cells. The drug aims to regulate the tumor microenvironment, suppress the survival of tumor cells, especially tumor stem cells, and prevent the metastasis and recurrence of cancer.

Program

Target and Modality

Indication

Discovery

Pre-clinical

Phase I/Ib

Phase II

Phase III

Collaborator

SLC-0111

CAIX small-molecule inhibitor

PDAC

Combination therapy with Gemcitabine in pancreatic cancer
Combination therapy with Gemcitabine in pancreatic cancer
Phase I/Ib

SLC-500

RON (Recepteur d'Origine Nantais) Inhibitor

SLC-500 is a small-molecule inhibitor of receptor tyrosine kinase RON (Recepteur d'Origine Nantais) that belongs to the mesenchymal-to-epithelial transition (MET) family. Further optimization is currently underway to improve its potency and selectivity.

Program

Target and Modality

Indication

Discovery

Pre-clinical

Phase I/Ib

Phase II

Phase III

Collaborator

SLC-500

RON small-molecule inhibitor

Solid Tumor

Solid Tumor
Solid Tumor
Discovery

SLC-600

Colony-stimulating factor 1 Receptor (CSF1R) Inhibitor

Our CSF1R program aims to develop a first-in-class CSF1R and ICI combination therapy to improve the ICI responsiveness and to overcome ICI resistance through the multifactorial modulation of immune responses.

Program

Target and Modality

Indication

Discovery

Pre-clinical

Phase I/Ib

Phase II

Phase III

Collaborator

SLC-600

CSF1R, small-molecule inhibitor

Solid Tumor

Solid Tumor
Solid Tumor
Discovery

SLC-700

Next-Gen Ferroptosis-Inducer

SLC-700 aims to develop a small-molecule inhibitor that possesses enhanced ferroptosis-inducing activity, with the goal of promoting ferroptosis of hypoxic cancer cells.

Program

Target and Modality

Indication

Discovery

Pre-clinical

Phase I/Ib

Phase II

Phase III

Collaborator

SLC-700

Undisclosed

Solid Tumor

Solid Tumor
Undisclosed
Solid Tumor
Discovery

Clinical Trials

On-going clinical studies: indications, patients, links to clinicaltrials.gov.

Program

Indication

Trial Number

Trial Name

Status

NSCLC Combination Therapy w/ Pembrolizumab

Phase 1b/2 trial with Pembro in NSCLC

Recruiting

Food effect study

A Phase 1, Open-Label, Randomized, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of SLC-391 in Healthy Adult Subjects

Completed

Solid Tumours

A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of the AXL Inhibitor SLC-391 Administered Orally to Subjects With Solid Tumours

Completed

Pancreatic Cancer Combination Therapy w/ Gemcitabine

Phase 1b trial with gemcitabine in pancreatic cancer

Recruiting

Solid tumours

Phase 1b trial with gemcitabine in pancreatic cancer

Completed

SLC-391

Indication:

NSCLC Combination Therapy w/ Pembrolizumab

Trial Number:

NCT05860296

Trial Name:

Phase 1b/2 trial with Pembro in NSCLC

Status:

Recruiting

Indication:

Food effect study

Trial Number:

NCT05278845

Trial Name:

A Phase 1, Open-Label, Randomized, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of SLC-391 in Healthy Adult Subjects

Status:

Completed

Indication:

olid Tumours

Trial Number:

NCT03990454

Trial Name:

A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of the AXL Inhibitor SLC-391 Administered Orally to Subjects With Solid Tumours

Status:

Completed
SLC-0111

Indication:

Pancreatic Cancer Combination Therapy w/ Gemcitabine

Trial Number:

NCT03450018

Trial Name:

Phase 1b trial with gemcitabine in pancreatic cancer

Status:

Recruiting

Indication:

Solid tumours

Trial Number:

NCT02215850

Trial Name:

Phase 1b trial with gemcitabine in pancreatic cancer

Status:

Completed